Health Care |
Bristol-Myers Squibb Dividend Announcement
Bristol-Myers Squibb declared a regular quarterly dividend in the amount of $.32 per share payable June 1, 2010 to shareholders of record on May 7, 2010.
At today''s $25.10 stock price the dividend yield is 5.10%.
Mar 5 · 10:03:00 AM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike
Australia Court Dismisses Claims Against Merck
Today, the Federal Court in Australia dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx.
The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court’s findings that were against MSD Australia and intend to appeal them.
Mar 5 · 9:59:00 AM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike
J&J Reaffirms Fiscal 2010 Guidance
Reuters.com is reporting that Johnson & Johnson announced that for fiscal 2010, it continues to expect earnings of $4.85 to $4.95 per share. According to Reuters Estimates, analysts on an average are expecting the Company to report earnings per share (EPS) of $4.92 for fiscal 2010.
At today's stock price of about $63.80, with a 2010 EPS of $4.92 that results in a forward PE of about 13. That seems like a flat out steal of a valuation for J&J.
Mar 5 · 9:55:00 AM · Source: Reuters.com
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike
Abbott and GSK Team on Skin Cancer Test
Abbott announced today that it has entered into an agreement with GlaxoSmithKline
(GSK) to develop a molecular diagnostic test intended for use as an aid in
selecting patients who may benefit from a skin cancer treatment in development
by GSK.
"This is an exciting continuation of our important collaboration with GSK, a
leading company in cancer immunotherapy research," said Stafford O'Kelly, head
of Abbott's molecular diagnostics business. "The agreement is indicative of
our commitment to personalized medicine and our focus on developing innovative
companion diagnostic tests that can be used to identify patients most likely
to benefit from specific cancer therapies."
Mar 4 · 10:44:00 AM · Source: Reuters.com
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike
Advertisement